Skip to content

Hydrocortisone Per-treatment Decrease Side Effects of Protamine Sulfate

The Role of Hydrocortisone Per-treatment in Decreasing Side Effects of Protamine Sulfate During Cardiac Surgeries, a Randomized Control Trial.

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04435912
Enrollment
200
Registered
2020-06-17
Start date
2019-07-04
Completion date
2020-06-01
Last updated
2020-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Pressure, Blood Pressure, Heart Rate

Keywords

Protamine sulfate, Hydrocortisone, Protamine Sulfate side effects

Brief summary

This study aims to compare the hemodynamic parameters within and between patients who received Protamine Sulfate (PS) with Hydrocortisone (HC) vs. Protamine Sulfate alone during cardiac surgeries.

Detailed description

the investigators hypothesized that patients received PS along with HC would have different results in intraoperative hemodynamic changes of the blood pressure - both Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) reading. Differences would also be expected for Heart rate (HR), Airway pressure and the usage of Adrenaline, Noradrenaline and Dobutamine. Patients who had cardiac surgery using cardiopulmonary bypass were screened and enrolled from 4/7/2019 to 30/4/2020. Inclusion criteria for patients were normal preoperative hemoglobin level, normal preoperative platelet count, no known defect of the coagulation system, and patients with unimpaired renal function (creatinine clearance \< 30 ml/kg/min). The patients were excluded if they were younger than 18 years, patients with known defect of the coagulation system, renal impairment, previous vasectomy, allergy to fish or unable to give consent form. The study carried out as a parallel-group, randomized, controlled trial with a 1:1 allocation ratio. Patients were screened for eligibility in the wards before being invited to participate in the research. After the invitation, the study was explained to patients. Those who agreed to participate in the study were asked to sign the consent form.

Interventions

DRUGHydrocortisone 200mg IV

single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine

Sponsors

University of Jordan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Investigator)

Masking description

Randomization envelopes kept closed until the completion of patient registration.

Intervention model description

Parallel group, randomized, controlled trial with 1:1 allocation ratio. Participants were Patients undergoing cardiac surgery using cardiopulmonary bypass.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who had cardiac surgery using cardiopulmonary bypass * Normal preoperative hemoglobin level * Normal preoperative platelet count * No known defect of the coagulation system * Patients with unimpaired renal function (creatinine clearance \< 30 ml/kg/min)

Exclusion criteria

* Patients younger than 18 years * Patients with known defect of the coagulation system * Renal impairment * Previous vasectomy * Allergy to fish * Unable to give consent form

Design outcomes

Primary

MeasureTime frameDescription
Blood pressurechanges of baseline blood pressure taken preoperatively and readings taken during 30 minutes after Protamine Sulfate was givenboth systolic, diastolic and mean arterial pressure

Secondary

MeasureTime frameDescription
Hemodynamic parameterschanges of baseline readings taken preoperatively and readings taken during 30 minutes after Protamine Sulfate was givenHeart rate (Beat Per Minute),

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026